Search

Your search for "Cybin" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Closing of Oversubscribed Private Placement

November 20, 2023

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has closed its private placement of unsecured convertible notes for aggregate gross proceeds of AUD$3,215,000, which represents an oversubscription of AUD$215,000 […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host CYB003 Topline Depression Study Review, Briefing

November 20, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that it will discuss its topline phase 2 safety and efficacy data for CYB003, its deuterated psilocybin analog being developed for the treatment of major depressive […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release, Discuss Topline Safety and Efficacy Data for MDD Study during Upcoming Event

November 16, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be hosting a research and development briefing on Nov. 30, 2023, at 10 a.m. ET in New York City. During the event, the company will release topline phase 2 safety and efficacy […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights

November 15, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023. The event, hosted by the Society for Neuroscience (“SFN”), is taking place Nov. 11-15, 2022, in Washington, D.C. “It is always exciting […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering

November 10, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced a firm commitment underwritten offering of 66,666,667 units of CYBN to one of its largest existing institutional shareholders and new institutional investors at a price […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit

November 3, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be represented at the 2023 Milken Institute Future of Health Summit. According to the announcement, Cybin CEO Doug Drysdale is slated to participate on a panel about innovations in mental health care; […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Anticipates Gross Proceeds of AUD$3M on Private Placement

November 2, 2023

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced a private placement of unsecured convertible notes. The placement is for of up to AUD$3 million and includes the ability to accept oversubscriptions of up to […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Breakthrough Results of Phase 2 Study of MDD Treatment

November 2, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting on interim results from its phase 2 study of CYB003, the company’s proprietary deuterated psilocybin analog, designed to treat major depressive disorder (“MDD”). According to the announcement, the results demonstrate […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones

November 1, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has released a clinical-stage program update and noted upcoming milestones for its development pipeline. Those milestones for CYB003, the company’s deuterated psilocybin analog program, include the completion of phase 2 topline safety and […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Files Prospectus Supplement, Closes Share Subscription Agreements

October 31, 2023

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has filed a shelf prospectus supplement to its Final Short Form Base Shelf Prospectus for the province of Québec and its Amended and […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder

October 31, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options. The company today announced phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent

October 26, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the European Patent Office (“EP”) has granted a patent protecting Cybin’s proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (“DMT”) programs. “Maintaining a secure intellectual property […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Reports on Company Progress in Q4 2023 Update

October 26, 2023

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has released a fourth-quarter 2023 company update. According to the update, the company has worked to simplify its business model, streamline workflow and […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program

October 25, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has been granted two patents by the United States Patent and Trademark Office; the patents offer protection for the company’s deuterated N, N-dimethyltryptamine (“DMT”) program, including deuterated analogs of DMT related to composition […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector

October 23, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to the terms of an arrangement agreement dated Aug. 28, 2023, […]

InvestorNewsBreaks

InvestorNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthen Position in Alternative Mental-Health Treatments Sector

October 18, 2023

Lucy Scientific Discovery (NASDAQ: LSDI), a pioneer in alternative mental-health treatments, is working to provide ingredients for effective mental-health treatment and therapies, including psilocybin and MDMA. According to a recent article spotlighting LSDI, the company is “well positioned” to support the mental-health space as it continues to grow. The article noted that mental-health issues are […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting

October 13, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the results of its annual and special meeting of shareholders, which was held Oct. 12, 2023. According to the announcement, 66 shareholders attended the meeting, either in person or by […]

InvestorNewsBreaks

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD$175,000 Private Placement

October 12, 2023

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed its previously announced private placement of unsecured convertible debentures to Jason Carroll, Tryp’s newly appointed CEO. The private placement was for gross proceeds of AUD$175,000. Tryp […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF) Starts Trading on the AQSE Growth Market

October 10, 2023

Mydecine Innovations (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has completed its admission to the Access segment of the AQSE Growth Market; the company begins trading on today at market open. According […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit

October 6, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be presenting at the Neuropsychiatric Drug Development Summit, slated for Oct. 11–12, 2023, in Boston. Cybin’s abstract, titled “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential,” […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) Common Shares Begin Listing on CSE

October 6, 2023

Mydecine Innovations (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, has received approval to list its common shares on the Canadian Securities Exchange (“CSE”). The company therefore submitted a request to the NEO […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

October 4, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has announced that its CEO Doug Drysdale will present at the Jefferies Inaugural Biotech CNS/Neuro Summit. The event is slated to take place in New York City on Oct. 11-12, 2023, with […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort

October 3, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing of the final cohort for its phase 2 CYB003 study. According to the announcement, the company anticipates reporting topline efficacy data later this year; Cybin is also looking forward to […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Expects UK Dual Listing Admission Next Month

September 28, 2023

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is expecting admission of its common shares to begin trading on the Access Segment of the AQSE (“AQSE”) Growth Market in the United […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study

September 27, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is giving kudos to Small Pharma Inc., a biotechnology company focused on short-duration, psychedelic-assisted therapies for mental-health conditions. Small Pharma is reporting positive safety, tolerability and efficacy data gathered from its phase Ib […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners with Fluence in Preparation to Advance CYB003 Toward Pivotal Studies

September 26, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of Cybin’s EMBARK facilitator training program in preparation […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference

September 25, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options. The company today announced that its CEO Doug Drysdale and the CEO of Small Pharma Inc., George Tziras, will participate in a panel discussion at the Cantor Global Healthcare Conference taking […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting

September 22, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is making plans for its annual shareholder meeting. The company announced that it has scheduled its 2023 Annual and Special Meeting of Shareholders; the meeting will be held virtually on Oct. 12, 2023, […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study

September 21, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company announced that it has completed enrollment in its phase 2 study of CYB003, a proprietary deuterated psilocybin analog program being developed for the potential treatment of major depressive […]

News Articles

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

September 8, 2023

Lucy Scientific Discovery (NASDAQ: LSDI) is an early-stage psychotropics manufacturing company focused on becoming the premier contract research, development and manufacturing organization for the emerging psychotropics-based medicines industry. The company holds a Controlled Drugs and Substances Dealer’s License granted by Health Canada’s Office of Controlled Substances. This specialized license authorizes LSDI to develop, sell, deliver […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notification of Approval for U.S. Patent Covering Deuterated Tryptamines

September 5, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has received notification that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,746,088, which covers composition of matter for deuterated tryptamine compounds and pharmaceutical composition; the grant provides exclusivity […]

InvestorNewsBreaks

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Receives CSE Listing Conditional Approval

August 31, 2023

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a publicly traded, prerevenue biopharmaceutical company, has applied for and received conditional approval to list its common shares on the Canadian Securities Exchange. The announcement noted that all customary CSE requirements must be met. According to the company, MYCOF officials expect trading to begin when the company has received […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Acquisition That Will Create ‘Clear Market Leader in Novel Psychedelic Therapeutics’

August 28, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, and Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF), a U.K.-based biotechnology company focused on short-duration psychedelic therapies for mental health conditions, today announced their entry into a definitive arrangement agreement. Under […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Renewed ATM Program of up to US$35M

August 24, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, announced that it has renewed its previously established at-the-market equity program. The “ATM Program” allows Cybin to issue and sell up to US$35,000,000 of common shares in the capital of the […]

Press Releases

Mushrooms, Inc. (OTC: MSRM) Announces Diverse Business Development Team Assembled to Drive Company Growth

August 23, 2023

ESTERO, Fla., Aug. 23, 2023 (GLOBE NEWSWIRE) — via IBN — Mushrooms Inc. (OTC:MSRM) – Mushrooms Inc., proudly introduces its newly-formed Business Development Team, strategically assembled to harness the momentum generated by the company’s new technology and Innovation lab development. Comprising accomplished professionals with diverse backgrounds, this team is poised to catapult Mushrooms Inc. into a new era […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Preparing for CYB003 Capsule Manufacturing for Potential Phase 3 Trial

August 17, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has begun preparations for good manufacturing practices (“GMP”) production of a capsule formulation of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of Major Depressive Disorder (“MDD”). According to […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures New US Patent Supporting Its CYB003 Program

August 15, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,724,985 to a deuterated psilocybin analog in Cybin’s CYB003 investigational drug program. “We are […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2024 Financial Results, Business Highlights

August 14, 2023

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting unaudited financial results for its first quarter, the period ended June 30, 2023, as well as recent business highlights. Financial numbers show cash total of C$9.3 million as of June 30, […]

InvestorNewsBreaks

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Closing of Marketed Public Offering

August 4, 2023

Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, has closed its previously announced overnight marketed public offering. In connection with the offering, the company issued an aggregate of 24,264,706 units of the company, each at a price of US$0.34, […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).